Pharvaris (PHVS) Competitors $16.91 +0.90 (+5.62%) Closing price 04:00 PM EasternExtended Trading$16.94 +0.04 (+0.21%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends PHVS vs. AKRO, CRNX, IMVT, MRUS, ACAD, APLS, MTSR, VKTX, MOR, and HCMShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Apellis Pharmaceuticals (APLS), Metsera (MTSR), Viking Therapeutics (VKTX), MorphoSys (MOR), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Akero Therapeutics Crinetics Pharmaceuticals Immunovant Merus ACADIA Pharmaceuticals Apellis Pharmaceuticals Metsera Viking Therapeutics MorphoSys HUTCHMED Akero Therapeutics (NASDAQ:AKRO) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, community ranking, dividends, earnings, institutional ownership and analyst recommendations. Does the MarketBeat Community prefer AKRO or PHVS? Akero Therapeutics received 81 more outperform votes than Pharvaris when rated by MarketBeat users. However, 66.67% of users gave Pharvaris an outperform vote while only 65.36% of users gave Akero Therapeutics an outperform vote. CompanyUnderperformOutperformAkero TherapeuticsOutperform Votes11765.36% Underperform Votes6234.64% PharvarisOutperform Votes3666.67% Underperform Votes1833.33% Is AKRO or PHVS more profitable? Akero Therapeutics' return on equity of -32.46% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -32.46% -29.83% Pharvaris N/A -38.52%-36.69% Do analysts prefer AKRO or PHVS? Akero Therapeutics presently has a consensus price target of $76.29, suggesting a potential upside of 70.05%. Pharvaris has a consensus price target of $40.50, suggesting a potential upside of 139.50%. Given Pharvaris' higher possible upside, analysts plainly believe Pharvaris is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Pharvaris 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor AKRO or PHVS? In the previous week, Akero Therapeutics had 9 more articles in the media than Pharvaris. MarketBeat recorded 15 mentions for Akero Therapeutics and 6 mentions for Pharvaris. Akero Therapeutics' average media sentiment score of 0.57 beat Pharvaris' score of 0.46 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, AKRO or PHVS? Akero Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$151.76M-$3.75-11.96PharvarisN/AN/A-$109.18M-$2.80-6.04 Which has more risk & volatility, AKRO or PHVS? Akero Therapeutics has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -3.02, suggesting that its share price is 402% less volatile than the S&P 500. SummaryAkero Therapeutics beats Pharvaris on 7 of the 12 factors compared between the two stocks. Remove Ads Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$884.22M$6.93B$5.63B$7.93BDividend YieldN/A2.72%4.89%4.05%P/E Ratio-6.046.1123.6418.73Price / SalesN/A219.83371.04119.11Price / CashN/A65.6738.0534.64Price / Book2.136.616.854.19Net Income-$109.18M$139.99M$3.19B$247.07M7 Day Performance9.45%-2.38%5.32%-2.84%1 Month Performance-2.65%-8.96%-1.07%-10.77%1 Year Performance-28.04%-5.03%12.34%0.47% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris1.7482 of 5 stars$16.91+5.6%$40.50+139.5%-32.2%$884.22MN/A-6.0430Short Interest ↑News CoverageAKROAkero Therapeutics4.0815 of 5 stars$45.54-7.3%$76.29+67.5%+61.1%$3.18BN/A-12.1430Insider TradeCRNXCrinetics Pharmaceuticals4.1868 of 5 stars$34.14-4.6%$72.64+112.8%-13.1%$3.17B$1.04M-9.15210Positive NewsIMVTImmunovant2.3144 of 5 stars$18.44-10.5%$43.55+136.1%-39.3%$3.13BN/A-7.04120Analyst ForecastInsider TradeMRUSMerus2.3089 of 5 stars$45.47-3.4%$85.77+88.6%+7.0%$3.11B$35.93M-11.5137Analyst ForecastACADACADIA Pharmaceuticals4.4695 of 5 stars$18.16-7.3%$24.00+32.2%-16.1%$3.02B$957.80M23.28510APLSApellis Pharmaceuticals4.2202 of 5 stars$24.06-4.3%$45.71+90.0%-57.0%$2.99B$715.22M-11.85770Short Interest ↑MTSRMetseraN/A$28.50+15.0%$47.00+64.9%N/A$2.94BN/A0.0081Quiet Period ExpirationVKTXViking Therapeutics4.3933 of 5 stars$25.70-11.0%$97.29+278.5%-56.0%$2.86BN/A-25.7020Analyst ForecastNews CoverageMORMorphoSysN/A$18.96flat$18.25-3.7%N/A$2.86B$238.28M-5.45730HCMHUTCHMED1.896 of 5 stars$15.91-3.3%$19.00+19.4%-5.1%$2.77B$610.81M0.001,988 Remove Ads Related Companies and Tools Related Companies Akero Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives Immunovant Alternatives Merus Alternatives ACADIA Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Metsera Alternatives Viking Therapeutics Alternatives MorphoSys Alternatives HUTCHMED Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 3/13/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHVS Stock Alerts